Eli Lilly and AtaiBeckley: AI and Psychedelic Biotech Converge
Eli Lilly's acquisition of Peter Thiel’s backed AtaiBeckley highlights growing investment in psychedelic biotech and the future of CNS drug discovery.
“The pharma industry is beginning to look at biological age as a surrogate endpoint to improve clinical trials."
Explore expert-led podcasts, pharmaceutical intelligence, life sciences insights and research-driven analysis from leading industry voices. Pharmatica delivers trusted biotech news, drug development trends and commercial intelligence for professionals across the pharmaceutical sector.
Eli Lilly's acquisition of Peter Thiel’s backed AtaiBeckley highlights growing investment in psychedelic biotech and the future of CNS drug discovery.
Cell and gene therapy CMC strategies, quality systems, and manufacturing innovation are critical to advanced therapy development and determine scalability.
One pivotal trial for FDA approval could accelerate drug development, reshape clinical trial strategy, and change the pharmaceutical regulatory landscape.
Learn how drug discovery scientists are evolving alongside AI, computational biology, and multidisciplinary research to accelerate therapeutic innovation.
Claude Science is a new AI R&D tool for drug discovery, integrating 60-plus scientific databases into one place. Here is what pharma R&D teams need to know.
The new European Life Sciences Strategy aims to accelerate pharmaceutical innovation through investment, regulatory reform, biotechnology, and AI capabilities.
Discover how digital CMC regulatory submissions, cloud collaboration, and AI accelerate the modernisation of manufacturing approvals and global pharma operations.
Deep learning is changing how clinical trials are designed, run, and analysed in 2026. Examine the tools, outcomes, and strategic risks shaping adoption.
From gut hormones to global therapeutics, GLP-1 drug discovery transformed obesity treatment through peptide engineering and incretin biology translation.
The FDA PreCheck Pilot Program aims to strengthen U.S. domestic drug manufacturing through regulatory engagement, manufacturing readiness, and advanced production.
AI in neuroscience is driving big pharma investment. Discover how AI neuroscience platforms are driving precision psychiatry and psychedelic therapeutics.
Explore the FDA's Master Protocol guidance and how basket, umbrella, and platform trials can improve clinical trial efficiency, especially in oncology and biologics.